



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid Drug Utilization Review (DUR) Board
Thursday, March 12, 2020, 1:00pm
DMAS 7B Conference Room
Agenda

1. **Call to Order and Introductions** – Chethan Bachireddy, MD, Chief Clinical Innovation Officer, Chief Medical Officer, Chair
2. **Minutes** - Approval of Minutes from December 12, 2019 meeting
3. **RetroDUR Criteria Estimates**
4. **New Drugs - Grid**
 - a. Baqsimi™ Nasal Powder (glucagon)
 - b. Brukinsa™ (zanubrutinib)
 - c. Fasentra® Pen (benralizumab)
 - d. Gvoke™ Syringe (glucagon)
 - e. Oxbryta™ (voxelotor)
 - f. Pretomanid
 - g. Drug Updates: New Generics; New Dosage Form/ Strength/ Biosimilar; PDL-Eligible; Physician Administered Drugs
5. **Specialty Drugs**
 - a. Crizanlizumab IV
 - b. Semaglutide Oral
 - c. MRx Pipeline
6. **Topics for Discussion**
 - a. Concurrent Use of Opioids and Benzodiazepines
 - b. SUPPORT Act Update
 - c. DUR Quarterly Newsletter



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

7. **Surveillance**
 - a. Opioid Use with Risk Factors and No Naloxone
 - b. Opioid Use with Risk Factors and Getting Naloxone
8. **Reports**
 - a. ProDUR
 - b. RetroDUR
 - c. Utilization Analysis
9. **Other Business**
10. **Adjournment**

DRAFT